Robert Burns
Recent Articles
Target Price Raised on Biotech Co. 09/25/2024
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company.
Leadership Cuts Won't Slow This Biotech 01/26/2024
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report.
Boston Biotech Could Have Blockbuster Sales 01/03/2024
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.
Biotech Receives First Approval; Drug Now Available 11/28/2023
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju.
Due to permission requirements, not all quotes are shown.
